PPMD Community

Santhera Presents Clinical Data of Catena® in Duchenne Muscular Dystrophy at the 2011 Congress of the World Muscle Society

Liestal, Switzerland, October 19, 2011 - Santhera Pharmaceuticals (SIX: SANN)
announced today that it will present data from the 2-year open-label study
(DELPHI-E study) evaluating Catena® for the treatment of Duchenne Muscular
Dystrophy [1], one of the most common and devastating types of muscular
dystrophy. The findings indicate that Catena® slowed the decline in respiratory
function compared to the expected natural history in patients with Duchenne
Muscular Dystrophy. Data from this study are in agreement with and confirm data
from a randomized controlled study (DELPHI study) of 12 months duration [2]. The
poster presentation will be given at the 16th International Congress of the
World Muscle Society in Almancil, Portugal on October 21, 2011.

http://www.cisionwire.com/santhera-pharmaceuticals-holding-ag-ext/r...

Sharon is attending WMS 2011. PRAYING TO GOD to hear many good news on Duchenne from WMS 2011.

Raktim

Favorite

0 members favorited this

▶ Reply to This

Replies to This Discussion

Permalink Reply by David on October 31, 2011 at 10:14pm

Sharon,

The abstract you posted included this statement: The change over time in respiratory as well as cardiac function data will be presented.

Can PPMD post those changes?

▶ Reply

Permalink Reply by Sharon Hesterlee on November 8, 2011 at 10:21am

Hi David:

I wasn't able to attend the Santhera presentation (I had to leave before the last day) so I don't have this information--I can email the company to see if they can send us the data.

Sharon

David said:

Sharon,

The abstract you posted included this statement: The change over time in respiratory as well as cardiac function data will be presented.

Can PPMD post those changes?